SEMAX 5MG
Semax is best known for its potential to enhance memory, neuroprotection, and recovery after neurological injury, with a well-documented mechanism centering on BDNF modulation and neurotransmitter (dopamine, serotonin) pathways.
$40.00
The information provided on this page is intended solely as a general summary. It does not encompass all potential research applications, handling procedures, safety precautions, interactions, or observed effects. These products are supplied strictly for laboratory and research purposes only. They are not intended for human consumption, medical use, veterinary use, or diagnostic purposes. This information must not be considered a substitute for professional expertise, judgment, or regulatory guidance.
Money Back Guarantee
Guaranteed Quality
Fast Shipping
10+ Years Experience
Frequently Bought Together
SEQUENCE/FORMULA
Sequence: Met-Glu-His-Phe-Pro-Gly-Pro
Molecular Formula: C37H51N9O10S
MOLECULAR WEIGHT
PUBCHEM CID
-
Studied for treating stroke, cognitive impairment, dementia, and inflammation of the optic nerve.
-
Used in Russia for brain trauma, ischemic injury, and as a neuroprotective agent.
-
Explored for enhancing memory, learning, and supporting mental performance under stress.
-
Semax upregulates BDNF and TrkB receptor expression, promoting neuroplasticity and neuroprotection.
-
Modulates dopamine and serotonin neurotransmitter systems for mood and cognitive improvement.
-
Influences gene expression in the central nervous system related to recovery and repair after injury.
-
Binds to melanocortin receptors in the brain, initiating protective cascades.
- Dolotov, O. V., et al. (2006). "Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus." Brain Research, 1117(1), 54-60.
- Eremin, K. O., et al. (2005). "Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents." Neurochemical Research, 30(12), 1493-1500.
- Gusev, E. I., et al. (2005). "Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency." Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 105(3), 35-40. (This reference is in Russian and highlights its clinical use in Russia).
- Koroleva, S. V., & Myasoedov, N. F. (2018). "Semax as a Universal Drug for Therapy and Research." Biology Bulletin Reviews, 8(3), 209-218.
